Cov neeg Amelikas no yav dhau los tau sib tham nrog peb, tab sis nws tau ntev heev ua ntej lawv tso lwm daim ntawv xaj kom yuav ib lub thawv.tirzeptide 5 mg. Tom qab qhov kev txiav txim tau muab tso rau, tus neeg siv khoom tau ntsib teeb meem thaum lub sijhawm them nyiaj: lawv sim ntau txoj hauv kev them nyiaj, tab sis lub kaw lus tau ua tsis tiav, tiv thaiv qhov kev txiav txim los ntawm kev nkag mus rau cov txheej txheem xa khoom. Cov neeg siv khoom rov qab xyuas lawv cov ntaub ntawv nyiaj txiag thiab sib txuas lus nrog tus neeg siv daim npav, ua ntau yam kev them nyiaj. Tom qab siv zog ntau, thaum kawg, ib qho kev them nyiaj tau pom tias ua tiav. Tom qab tau txais qhov kev pom zoo, peb tam sim ntawd npaj rau kev xa khoom raws cai thiab hloov kho cov ntaub ntawv taug qab rau cov neeg siv khoom.
Tam sim no, lub pob tau ntse tuaj txog hauv Tebchaws Meskas. Qhov tseeb logistics xwm txheej qhia tau hais tias nws tau ua tiav kev lis kev cai clearance thiab tam sim no tab tom ua tiav ntawm lub chaw faib khoom hauv zos. Nws yuav sai sai no mus rau theem kev xa khoom. Txawm hais tias muaj qee qhov kev poob qis los ntawm kev tso qhov kev txiav txim kom ua tiav cov nyiaj them poob haujlwm, uas ua rau lub sijhawm ua tiav tag nrho, qhov kev txiav txim tau ua tiav tiav. Cov neeg muas zaub yuav tau txais cov khoom nyob rau hauv lub neej yav tom ntej, thiab kev sib txuas lus thiab kev koom tes nyob rau hauv tag nrho cov txheej txheem tseem du.
kev lag luam
Kev tswj ntshav qab zib: Tshaj li qhov muaj peev xwm hypoglycemic ntawm ib lub hom phiaj
Qhov tseem ceeb ntawm kev ua tau zoo ntawm tirzepatide hauv kev tswj hwm hom 2 mob ntshav qab zib mellitus feem ntau tshwm sim hauv nws qhov txo qis ntawm glycated hemoglobin (HbA1c).
Kev txo qis: Hauv SURPASS series ntawm kev sim tshuaj, Tirzepatide tuaj yeem txo HbA1c txog li 2.24%, uas yog ib qho tseem ceeb ntawm cov tshuaj zoo sib xws.
Lub taub hau - mus rau - taub hau superior rau GLP-1 receptor agonists:Hauv kev sib piv 40-lub lim tiam, peb pawg koob tshuaj Tirzepatide (5mg, 10mg, 15mg) tsis qis dua thiab zoo dua rau semaglutide 1.0mg hauv kev txo HbA1c. Qhov tsawg tshaj plaws squares txhais tau tias qhov sib txawv ntawm kev kho mob yog -1.9kg, -3.6kg, thiab -5.5kg (P<0.001).
Ib qho kev xav tsis thoob ntawm kev ua tiav cov ntshav qabzib ib txwm:Hauv pawg koob tshuaj ntau tshaj plaws, kwv yees li 50% ntawm cov neeg mob tau ua tiav cov ntshav qabzib ib txwm muaj ntawm HbA1c < 5.7%, uas txhais tau hais tias ib feem tseem ceeb ntawm cov neeg mob tau pom kev txhim kho hauv lawv cov - cell function.
Glucose-nyob ntawm insulin secretion:Tirzepatide txhim kho insulin secretion los ntawm pancreatic -cells nyob rau hauv thawj thiab thib ob theem nyob rau hauv ib tug qabzib - raws li, thaum inhibiting lub secretion ntawm glucagon los ntawm -cells, yog li txo cov piam thaj tso zis los ntawm lub siab. Cov txheej txheem no ua rau nws txoj kev pheej hmoo ntawm hypoglycemia tsawg heev thaum siv ib leeg.
Weight Management: Breakthrough Weight Loss Data
Yog tias txo qis ntshav qab zib yog "kev txawj ntse" ntawm Tirzepatide, ces qhov poob phaus yog qhov zoo tshaj plaws "killer feature" ntawm cov tshuaj no.
Cov ntaub ntawv thoob ntiaj teb: Qhov kev poob phaus yog qhov tsis tau muaj dua
Hauv SURMOUNT-1 Kev sim thoob ntiaj teb Phase III uas suav nrog 2,539 tus neeg tsis muaj ntshav qab zib rog lossis cov neeg laus rog rog:
Pawg 15mg koob tshuaj tau txo qhov hnyav nruab nrab ntawm 20.9% (kwv yees li 22.5 kg) ntawm 72 lub lis piam, cim thawj zaug hauv Phase III qhov kev sim tshuaj uas cov tshuaj tau ua tiav qhov hnyav poob qis tshaj 20% qhov pib.
Pab pawg koob tshuaj 10mg tau ua tiav qhov hnyav nruab nrab ntawm 19.5%, thiab pawg 5mg kuj tau pom cov txiaj ntsig tseem ceeb.
85% mus rau 91% ntawm cov kev kawm tau ua tiav qhov hnyav dua los yog sib npaug li 5% ntawm 72 lub lis piam, thaum pawg placebo ua tiav tsuas yog 35% (P <0.001).
Hauv 15mg pab pawg, 63% ntawm cov neeg kawm tau ntsib qhov hnyav txo tsawg kawg yog 20%, qhov feem ntau tshwj xeeb ntawm txhua qhov kev sim tshuaj ntsuam xyuas ntawm cov tshuaj poob phaus.
Suav pej xeem cov ntaub ntawv: sib npaug zoo heev
SURMOUNT-CN txoj kev tshawb fawb, luam tawm hauv JAMA xyoo 2024, tau coj los ntawm pab pawg xibfwb Li Xiaoying los ntawm Zhongshan Tsev Kho Mob ntawm Fudan University thiab tau ua hauv 29 lub chaw kho mob thoob plaws Suav teb:
Tag nrho ntawm 210 tus neeg laus Suav nrog BMI ntawm 28 kg / m² lossis siab dua, lossis BMI ntawm 24 kg / m² nrog tsawg kawg ib qhov hnyav - cuam tshuam txog kev sib kis tau suav nrog.
Thaum 52 lub lis piam, pawg 15mg ua tiav qhov hnyav poob ntawm 17.5% (16.1 kg), pawg 10mg ua tiav qhov hnyav poob ntawm 13.6% (12.3 kg), thiab cov placebo pab pawg tsuas poob 2.1 kg.
85.8% (hauv pawg 15mg) thiab 87.7% (hauv pawg 10mg) ntawm cov neeg tuaj koom tau ua tiav kev kho mob hnyav hnyav ntau dua lossis sib npaug li 5%.
61.4% (hauv 15mg pawg) ntawm cov neeg koom tau poob ntau dua lossis sib npaug li 15% ntawm lawv qhov hnyav, deb tshaj li ntawm pawg placebo.
Cov ntaub ntawv no qhia tau hais tias kev poob phaus ntawm Tirzepatide hauv cov pej xeem Suav tau zoo ib yam nrog cov ntaub ntawv thoob ntiaj teb, thiab tsis yog qhov tshwm sim tshwm sim tshwj xeeb rau qee pawg.
Kev kho lub cev muaj pes tsawg leeg: Tsis yog "poob phaus" xwb
Kev poob phaus ua tiav nrog tirzepatide tsis yog tsuas yog poob dej xwb, tab sis qhov txo qis hauv cov rog thiab txhim kho lub cev muaj pes tsawg leeg.
Tag nrho cov rog cov ntsiab lus poob los ntawm qhov nruab nrab ntawm 33.9%, thaum cov placebo pab pawg tsuas yog txo los ntawm 8.2%. Qhov kwv yees qhov sib txawv ntawm kev kho mob yog -25.7 feem pua cov ntsiab lus (95% CI, -31.4 txog -20.0).
Qhov sib piv ntawm tag nrho cov rog cov ntsiab lus rau tag nrho cov nqaij ntshiv cov ntsiab lus tau txo los ntawm 0.93 ntawm lub hauv paus mus rau 0.70 (15mg pawg), qhia tau hais tias cov nqaij pob txha tau khaws cia zoo thaum lub sij hawm poob.
Lub duav ncig txo qis: Hauv SURMOUNT- txoj kev tshawb fawb CN, pawg 15mg tau txo qhov nruab nrab ntawm 14.5 cm hauv lub duav ncig, 10mg pawg tau txo qis ntawm 11.4 cm, thiab pawg placebo tsuas muaj 2.6 cm. Lub duav ncig yog qhov qhia tau qhov tseeb ntawm cov roj visceral, thiab cov ntaub ntawv no qhia txog qhov txo qis hauv cov roj visceral.
Cov qib ntawm adiponectin, qhov muaj roj ntau ntxiv: Txoj kev tshawb fawb pom tias Tirzepatide tuaj yeem nce qib adiponectin nce mus txog 26% (10mg koob, 26 lub lis piam). Cov rog no koom nrog kev tswj hwm ntawm cov piam thaj thiab lipid metabolism, thiab nws qhov kev nce ntxiv muaj qhov tseem ceeb rau kev noj qab haus huv metabolic.
Multidimensional kev pab cuam ntawm lub plawv thiab metabolic noj qab haus huv
Kev ua tau zoo ntawm tirzepatide txuas ntxiv tshaj cov ntshav qab zib thiab qhov hnyav; nws kuj qhia tau hais tias muaj kev txhim kho zoo hauv cov hlab plawv thiab cov ntsuas metabolic.
Kev txhim kho ntshav siab
Hauv kev tshaj tawm - kev tshuaj xyuas ntawm SUMMIT kev sim, qhov kwv yees txo qis hauv cov ntshav ntim hauv pawg Tirzepatide tau cuam tshuam nrog kev txo qis ntshav siab, txo qis microalbuminuria, thiab nce 6-feeb taug kev deb.
Optimization ntawm lipid profile
Qhov kev tshawb fawb SURMOUNT-CN tau qhia tias kev yoo mov insulin, tsawg heev -cov roj lipoprotein ceev (VLDL-C), thiab triglycerides tau txhim kho zoo dua piv rau pawg placebo.
Ntshav qabzib thiab insulin rhiab heev
Hauv cov neeg mob uas muaj ntshav qab zib hom 2 (kev tshawb fawb SURMOUNT-2), ntawm 72 lub lis piam, pawg 15mg tau pom qhov txo qis hauv HbA1c, thiab feem ntau ntawm cov neeg uas xav tau ob lossis ntau dua cov tshuaj tiv thaiv kab mob ntshav qab zib tau txo qis los ntawm 38% mus rau 32%, qhia tias lub nra hnyav rau qee cov neeg mob tau txo qis.
Synergistic nyhuv ntawm cov tshuaj insulin sib xyaw
Hauv kev sim SURPASS-5 thiab SURPASS-6, Tirzepatide ua ke nrog basal insulin (insulin glargine lossis lispro insulin) txhim kho HbA1c thaum txo qis cov xwm txheej hyperglycemic thiab hypoglycemic, ua kom pom qhov zoo ntawm kev tswj hwm los ntawm ntau lub tshuab ua ke.
Vim li cas "dual{0}}targeting" muaj zog dua li "single-targeting"?
Txhawm rau kom nkag siab txog qhov ua tau zoo ntawm Tirzepatide, ib tus yuav tsum rov qab mus rau nws qhov tshwj xeeb tsim tshuaj.
Lub luag haujlwm ntxiv ntawm GIP txoj hauv kev: Cov kev tshawb fawb ua ntej tau lees paub tias GIP tuaj yeem txo qis kev noj zaub mov thiab nce kev siv zog. Thaum ua ke nrog kev ua ntawm GLP-1 receptor agonists, cov teebmeem ntawm cov ntshav qabzib thiab lub cev hnyav yog ntau dua li qhov ua tiav los ntawm ob txoj hauv kev tau qhib ib leeg.
Kev tswj kev noj qab haus huv hauv nruab nrab: Ib zaug -kev txhaj tshuaj subcutaneous txhua lub lim tiam ntawm ultra-ntev- ua yeeb yam dual receptor agonist tuaj yeem ncav cuag lub hauv paus paj hlwb (CNS) thiab cov ntaub so ntswg peripheral adipose. Qhov ntxiv GIP receptor agonism ua rau qhov kev xav ntawm kev ua kom puv nkaus, uas yog ib yam dab tsi uas endogenous GIP tsis tuaj yeem ua tiav vim nws lub neej luv luv -.
Kev taw qhia tsis zoo: Ntawm GLP-1 receptor, Tirzepatide nyiam cAMP tiam es tsis yog -arrestin recruitment. Qhov "kev tsis ncaj ncees agonism" no ntseeg tau ntxiv txhim kho cov tshuaj insulin secretion efficiency.
In short, tirzepatide is not simply the combination of two drugs; rather, a single molecule simultaneously activates two metabolic pathways, producing a synergistic effect where "1+1>2."
Tirzepatide, nrog nws qhov tshwj xeeb dual GIP / GLP-1 receptor agonist mechanism, tau xa cov txiaj ntsig kev kho mob thoob plaws plaub qhov tseem ceeb: kev tswj glycemic, tswj qhov hnyav, kho lub cev muaj pes tsawg leeg, thiab kev txhim kho plawv metabolic. Los ntawm 2.24% txo qis hauv HbA1c mus rau qhov hnyav poob ntau dua 20%, los ntawm 33.9% txo cov rog rog mus rau 26% nce hauv adiponectin, txhua daim ntaub ntawv taw qhia rau tib qhov kev txiav txim siab: Qhov no yog lub hom phiaj, ntau cov txiaj ntsig metabolic. Nws sawv cev yog ib qho tseem ceeb tshaj plaws hauv kev ua haujlwm ntawm enteroinsulin hauv kaum xyoo dhau los thiab tau qhib txoj hauv kev tshiab rau kev tswj hwm ntawm hom 2 mob ntshav qab zib thiab rog rog.
